CRBP

Corbus Pharmaceuticals Holdings, Inc.
CAPPED RATING

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.7
EV / EBITDA 0.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -59.7%
Price Return 12M -62.6%
Catalyst Signal 0.00
Market Cap $76.0M
TTM Revenue N/A
Price / Sales N/A
ROE -95.6%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) B (3.4) D (1.2) D- (0.9) C+ (2.6) C (2.4)
2026-11-04 B+ (3.7) B (3.3) D (1.2) D- (1.0) C+ (2.7) C (2.4)
2026-10-28 B+ (3.7) B (3.2) D (1.2) D (1.2) C+ (2.7) C (2.4)
2026-10-21 B+ (3.7) B (3.2) D (1.2) D (1.2) C+ (2.6) C (2.4)
2026-10-14 B+ (3.7) B (3.2) D (1.2) D (1.5) C+ (2.6) C (2.4)
Page 1 of 4